CMAJ • February 28, 2006; 174 (5). doi:10.1503/cmaj.1030034.
© 2006 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendices
Right arrow Correction (v174,p1450)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, T.
Right arrow Articles by Lee, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, T.
Right arrow Articles by Lee, S. S.
Related Collections
Right arrow Other infectious diseases

Review

Hepatitis C: a review for primary care physicians

Tom Wong and Samuel S. Lee

From the Public Health Agency of Canada and the University of Ottawa, Ottawa, and the University of Toronto, Toronto, Ont. (Wong), and from the Department of Medicine, Liver Unit, University of Calgary, Calgary, Alta. (Lee)

Correspondence to: Dr. Tom Wong, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, Jeanne Mance Bldg., Room 647B, Tunney's Pasture, PL1906B, Ottawa ON K1A 0K9; tom_wong{at}hc-sc.gc.ca

Abstract

Primary care physicians see many of the estimated 250 000 Canadians chronically infected with the hepatitis C virus (HCV). Of this number, about one-third are unaware they are infected, which constitutes a large hidden epidemic. They continue to spread HCV unknowingly and cannot benefit from advances in antiviral therapy that may clear them of the virus. Many HCV-infected people remain asymptomatic, which means it is important to assess for risk factors and test patients accordingly. The third-generation enzyme immunoassay for HCV antibodies is a sensitive and specific test, although the presence of the virus can be confirmed by polymerase chain reaction testing for HCV RNA in some circumstances. Pegylated interferon-{alpha} and ribavirin combination therapy clears the virus in about 45%–80% of patients, depending on viral genotype. Preventive strategies and counselling recommendations are also reviewed.




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. M. Dougherty, H. Guo, G. Westby, Y. Liu, E. Simsek, J.-T. Guo, A. Mehta, P. Norton, B. Gu, T. Block, et al.
A Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen Secretion
Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4427 - 4437.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
S. Khan and W.A.C. Sewell
Hepatitis C: reviewing the options.
Can. Med. Assoc. J., July 4, 2006; 175(1): 63 - 63.
[Full Text] [PDF]

Home page
 CMAJHome page
M. R. Pijak
Hepatitis C: reviewing the options.
Can. Med. Assoc. J., July 4, 2006; 175(1): 63 - 64.
[Full Text] [PDF]

eLetters:

Read all eLetters

Asia cannot ignore the dangers of the hidden epidemic- Hepatitis C
Prof. Govindasamy Agoramoorthy
CMAJ, 6 Mar 2006 [Full text]
Hepatitis C and urticarial syndromes
Sujoy Khan
CMAJ, 6 Apr 2006 [Full text]
Are liver biopsy and viral load measurement really unnecessary in HCV genotype 2 or 3?
Michal R. Pijak
CMAJ, 19 Apr 2006 [Full text]